CL2017000819A1 - Métodos para separar diastereoisoméros de fosfato - Google Patents
Métodos para separar diastereoisoméros de fosfatoInfo
- Publication number
- CL2017000819A1 CL2017000819A1 CL2017000819A CL2017000819A CL2017000819A1 CL 2017000819 A1 CL2017000819 A1 CL 2017000819A1 CL 2017000819 A CL2017000819 A CL 2017000819A CL 2017000819 A CL2017000819 A CL 2017000819A CL 2017000819 A1 CL2017000819 A1 CL 2017000819A1
- Authority
- CL
- Chile
- Prior art keywords
- phosphate
- methods
- gemeitabine
- alaninyl
- diastereoisomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>ESTA SOLICITUD TIENE RELACIÓN CON UN MÉTODO PARA SEPARAR LOS DIASTEREOISÓMEROS DE FOSFATO DE GEMEITABINA-[ FENIL-BENZOXI-L-ALANINILO )]-FOSFATO ( NUC - 1031) USANDO CRISTALIZACIÓN. EN PARTICULAR, LA CRISTALIZACIÓN A PARTIR DE ISOPROPIL ALCOHOL PROPORCIONA GEMEITABINA-[FENILBENZOXI-L-ALANINILO)]-(S)-FOSFATO EN FORMA ALTA DISATEREOISOMÉRICAMENTE PURA. ESTA SOLICITUD TAMBIÉN TIENE RELACIÓN CON UNA FORMA CRISTALINA DE GEMEITABINA-[FENIL-BENZOXI-L-ALANINILO)]-(S)-FOSFATO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417644.0A GB201417644D0 (en) | 2014-10-06 | 2014-10-06 | Method of separating phosphate diastereoisomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000819A1 true CL2017000819A1 (es) | 2017-11-03 |
Family
ID=51946917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000819A CL2017000819A1 (es) | 2014-10-06 | 2017-04-04 | Métodos para separar diastereoisoméros de fosfato |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10669300B2 (es) |
| EP (2) | EP3204398B1 (es) |
| JP (2) | JP6893172B2 (es) |
| KR (1) | KR102532498B1 (es) |
| CN (2) | CN107108682B (es) |
| AU (2) | AU2015329767B2 (es) |
| CA (1) | CA2959977C (es) |
| CL (1) | CL2017000819A1 (es) |
| CY (1) | CY1123061T1 (es) |
| DK (1) | DK3204398T3 (es) |
| EA (1) | EA033118B1 (es) |
| ES (1) | ES2793957T3 (es) |
| GB (1) | GB201417644D0 (es) |
| HR (1) | HRP20200849T1 (es) |
| HU (1) | HUE050882T2 (es) |
| IL (1) | IL251125B (es) |
| LT (1) | LT3204398T (es) |
| MA (1) | MA41039B1 (es) |
| ME (1) | ME03730B (es) |
| MX (2) | MX2017004446A (es) |
| MY (1) | MY183302A (es) |
| PH (1) | PH12017500586A1 (es) |
| PL (1) | PL3204398T3 (es) |
| PT (1) | PT3204398T (es) |
| RS (1) | RS60634B1 (es) |
| SG (2) | SG10201902952SA (es) |
| SI (1) | SI3204398T1 (es) |
| WO (1) | WO2016055769A1 (es) |
| ZA (1) | ZA201701723B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| PT3150616T (pt) | 2012-11-16 | 2017-06-09 | Univ College Cardiff Consultants Ltd | Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato |
| WO2015198058A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Gemcitabine prodrugs |
| ES2655820T3 (es) | 2014-06-25 | 2018-02-21 | NuCana plc | Formulación que comprende un profármaco de gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| CN106478753A (zh) * | 2015-09-16 | 2017-03-08 | 博瑞生物医药（苏州）股份有限公司 | 一种nuc‑1031单一异构体的制备方法和用途 |
| CN106543252A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的制备方法及其中间体 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| WO2017098252A1 (en) | 2015-12-11 | 2017-06-15 | Nucana Biomed Limited | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| WO2018019188A1 (zh) * | 2016-07-23 | 2018-02-01 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的多晶型及其制备方法 |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN107400156B (zh) * | 2017-09-19 | 2020-01-31 | 北京大学 | 一种分离麦角甾烷型三萜25r-与25s-差向异构体的方法 |
| CN115028594A (zh) * | 2020-06-03 | 2022-09-09 | 吴卫东 | 恩替他滨药用前体化合物及其制备方法和医学用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1254092B1 (en) * | 2000-02-11 | 2004-01-21 | Degussa AG | Resolution of dl-racemic mixtures |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| FR2954310B1 (fr) * | 2009-12-18 | 2014-07-25 | Univ Rouen | Procede de dedoublement d'enantiomeres par evapocristallisation preferentielle |
| PT3150616T (pt) * | 2012-11-16 | 2017-06-09 | Univ College Cardiff Consultants Ltd | Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato |
| WO2014204856A1 (en) | 2013-06-17 | 2014-12-24 | Catabasis Pharmaceuticals, Inc. | Fatty acid anticancer derivatives and their uses |
| MX2016006919A (es) * | 2013-11-27 | 2016-08-17 | Idenix Pharmaceuticals Llc | Nucleotidos para el tratamiento de cancer de higado. |
| ES2655820T3 (es) * | 2014-06-25 | 2018-02-21 | NuCana plc | Formulación que comprende un profármaco de gemcitabina |
| WO2015198058A1 (en) | 2014-06-25 | 2015-12-30 | Nucana Biomed Limited | Gemcitabine prodrugs |
| ES2830784T3 (es) | 2014-07-22 | 2021-06-04 | NuCana plc | Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| KR20180021697A (ko) | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| WO2017098252A1 (en) | 2015-12-11 | 2017-06-15 | Nucana Biomed Limited | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| RS60211B1 (sr) | 2015-12-23 | 2020-06-30 | NuCana plc | Kombinovana terapija |
| CA3008769A1 (en) | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
-
2014
- 2014-10-06 GB GBGB1417644.0A patent/GB201417644D0/en not_active Ceased
-
2015
- 2015-09-29 CN CN201580054225.8A patent/CN107108682B/zh active Active
- 2015-09-29 LT LTEP15782005.1T patent/LT3204398T/lt unknown
- 2015-09-29 CA CA2959977A patent/CA2959977C/en active Active
- 2015-09-29 SG SG10201902952SA patent/SG10201902952SA/en unknown
- 2015-09-29 ES ES15782005T patent/ES2793957T3/es active Active
- 2015-09-29 MX MX2017004446A patent/MX2017004446A/es active IP Right Grant
- 2015-09-29 PL PL15782005T patent/PL3204398T3/pl unknown
- 2015-09-29 JP JP2017518474A patent/JP6893172B2/ja active Active
- 2015-09-29 CN CN202011494200.9A patent/CN112552362A/zh active Pending
- 2015-09-29 MY MYPI2017000434A patent/MY183302A/en unknown
- 2015-09-29 MX MX2020003758A patent/MX2020003758A/es unknown
- 2015-09-29 EP EP15782005.1A patent/EP3204398B1/en active Active
- 2015-09-29 EP EP20172701.3A patent/EP3725794A1/en not_active Withdrawn
- 2015-09-29 US US15/514,673 patent/US10669300B2/en active Active
- 2015-09-29 ME MEP-2020-104A patent/ME03730B/me unknown
- 2015-09-29 MA MA41039A patent/MA41039B1/fr unknown
- 2015-09-29 SI SI201531226T patent/SI3204398T1/sl unknown
- 2015-09-29 PT PT157820051T patent/PT3204398T/pt unknown
- 2015-09-29 SG SG11201701885UA patent/SG11201701885UA/en unknown
- 2015-09-29 AU AU2015329767A patent/AU2015329767B2/en active Active
- 2015-09-29 RS RS20200611A patent/RS60634B1/sr unknown
- 2015-09-29 WO PCT/GB2015/052839 patent/WO2016055769A1/en active Application Filing
- 2015-09-29 HU HUE15782005A patent/HUE050882T2/hu unknown
- 2015-09-29 KR KR1020177012012A patent/KR102532498B1/ko active IP Right Grant
- 2015-09-29 EA EA201790794A patent/EA033118B1/ru unknown
- 2015-09-29 DK DK15782005.1T patent/DK3204398T3/da active
-
2017
- 2017-03-09 ZA ZA2017/01723A patent/ZA201701723B/en unknown
- 2017-03-13 IL IL251125A patent/IL251125B/en active IP Right Grant
- 2017-03-30 PH PH12017500586A patent/PH12017500586A1/en unknown
- 2017-04-04 CL CL2017000819A patent/CL2017000819A1/es unknown
-
2020
- 2020-04-23 JP JP2020076624A patent/JP6967625B2/ja active Active
- 2020-05-25 CY CY20201100477T patent/CY1123061T1/el unknown
- 2020-05-26 HR HRP20200849TT patent/HRP20200849T1/hr unknown
- 2020-06-05 AU AU2020203714A patent/AU2020203714B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000819A1 (es) | Métodos para separar diastereoisoméros de fosfato | |
| CL2018000096A1 (es) | Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos. | |
| CL2018000088A1 (es) | Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| CL2016000238A1 (es) | Polimorfo de los inhibidores de la syk | |
| CO2017012893A2 (es) | Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas | |
| CR20140534A (es) | Proceso para la preparación de treprostinil y derivado de los mismos | |
| CL2019002793A1 (es) | Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma. | |
| AR097481A1 (es) | Cocristales energéticos para el tratamiento de una formación subterránea | |
| UY34108A (es) | ?proceso para la fabricación de sustratos revestidos?. | |
| EA201600429A1 (ru) | Способ очистки 2,5-дихлорфенола | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| CL2018000087A1 (es) | Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| AR101434A1 (es) | Método para producir (r)-1,1,3-trimetil-4-aminoindano | |
| CO2017009130A2 (es) | Métodos para preparar buprenorfina | |
| EA201692288A1 (ru) | Способ получения фосфорсодержащих циангидринов | |
| EA201691006A1 (ru) | Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза | |
| AR101368A1 (es) | Forma cristalina de sofosbuvir y proceso para su preparación | |
| UY34719A (es) | Proceso para la producción de inhibidores de crr | |
| CL2016000583A1 (es) | Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica. | |
| BR112015026703A2 (pt) | revestimento alimentício artificial, método para a remoção e método para a fabricação do mesmo | |
| CL2017001633A1 (es) | Método de manufactura de proteína. | |
| EA201791329A1 (ru) | Новые кристаллические формы мононатриевой соли форамсульфурона | |
| CL2016000951A1 (es) | Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer. |